Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$13.04 USD

13.04
7,158,778

+0.14 (1.09%)

Updated May 16, 2024 11:43 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More

by Kinjel Shah

Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

by Sundeep Ganoria

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment

by Zacks Equity Research

Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.

Fast-paced Momentum Stock Novavax (NVAX) Is Still Trading at a Bargain

by Zacks Equity Research

Novavax (NVAX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%

by Zacks Equity Research

Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.

Novavax's (NVAX) COVID Jab Gets Full Approval in Europe

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.

Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Sanghamitra Saha headshot

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

by Sanghamitra Saha

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

by Zacks Equity Research

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

Why Is Novavax (NVAX) Down 14.7% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

by Zacks Equity Research

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of May 8, 2023

by Panel Of Zacks Experts

A Biotech Company Developing Vaccines and a Restaurant Stock with Earnings Growth.

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -0.89% and 40.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

by Kinjel Shah

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $7.15, marking a +1.56% move from the previous day.

Amgen (AMGN) Q1 Earnings Beat Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $7.53, moving -1.31% from the previous trading session.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $6.59, marking a -1.05% move from the previous day.

Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $5.76, marking a -0.35% move from the previous day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.